What are the new drugs for the treatment of plaque psoriasis?

Plaque psoriasis is the most common form of psoriasis, accounting for about 80% of all cases. Also known as psoriasis vulgaris, this is a chronic skin condition with visible symptoms such as raised, red patches covered with white or silvery scales on the skin. These patches, known as plaques, are known to occur anywhere on the body, but are commonly found on the elbows, knees, scalp, and lower back.  Various drugs and lines of treatment are presently used for treating the condition, with new drug discoveries helping to manage the condition effectively. A question commonly asked by patients is – what are the new drugs for the treatment of plaque psoriasis? Following subsection offer answers to the question along with desired background information on the condition and its treatment.

Overview of plaque psoriasis

The exact cause of plaque psoriasis is not fully established, and is believed to be attributed to a combination of genetic, immune, and environmental factors. Plaque psoriasis is often linked to an autoimmune disorder, wherein the immune system mistakenly attacks healthy skin cells, leading to the rapid growth of skin cells and the formation of plaques. The condition affects the quality of life, due to the physically uncomfortable and emotionally distressing situation. Treatment options for plaque psoriasis include topical corticosteroids, topical calcineurin inhibitors, vitamin D analogues, retinoids, phototherapy, systemic medications, and supportive measures.

Symptoms of plaque psoriasis?

The common symptoms of plaque psoriasis include the following:

Treatment options for plaque psoriasis?

There are several treatment options available for plaque psoriasis, which can be tailored to the severity of the condition and the individual patient’s needs. Common treatment options are as listed below:

What are the new drugs for the treatment of plaque psoriasis?

New drugs have emerged in recent years for treating plaque psoriasis, and these drugs belong to the class of biologic therapies. These targeted medications work by blocking specific components of the immune system involved in the development of psoriasis. A few of the newer drugs include the following:

These newer drugs have shown promising results in clinical trials and have been approved for the treatment of plaque psoriasis in certain countries. They offer additional options for patients who may not have responded to traditional treatments or who require alternative treatment approaches due to contraindications or intolerances to other medications.

What is tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu)

Deucravacitinib (Sotyktu), also known by its brand name Sotyktu, is a novel prescription only medication that belongs to the class of tyrosine kinase inhibitors. The drug specifically targets the enzyme tyrosine kinase 2, that is involved in signaling pathways associated with the immune response and inflammation. This enzyme plays a key role in various autoimmune and inflammatory diseases, including psoriasis.  Deucravacitinib works by selectively inhibiting TYK2, modulating the immune response and reducing inflammation. By inhibiting TYK2, deucravacitinib disrupts the signaling pathways responsible for the production of various pro-inflammatory cytokines, IL-12, IL-23, and IFN-gamma.

Deucravacitinib is administered orally as tablets and is typically prescribed as a once-daily medication. Clinical trials have demonstrated that deucravacitinib can significantly improve the signs and symptoms of plaque psoriasis, including skin clearance and quality of life, in patients with moderate to severe disease.

Leave a Reply